Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) report new data that support the hypothesis that remdesivir, a drug with broad antiviral activity, may be a promising treatment against Middle East respiratory syndrome coronavirus (MERS-CoV).

In the team’s experiments, remdesivir reduced the severity of disease, virus replication, and damage to the lungs when administered to infected monkeys. The authors suggest that it be considered for implementation in clinical trials and that it may also have utility for other, related coronaviruses, such as SARS-CoV-2 (previously known as 2019-nCoV).

The experimental antiviral remdesivir successfully prevented disease in rhesus macaques infected with MERS-CoV. Remdesivir prevented disease when administered before infection and improved the condition of macaques when given after the animals already were infected.

The data is presented in a paper published in Proceedings of the National Academy of Sciences titled, “Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.

Remdesivir has previously protected animals against a variety of viruses in lab experiments. The drug has been shown experimentally to effectively treat monkeys infected with Ebola and Nipah viruses. Remdesivir also has been investigated as a treatment for Ebola virus disease in people.

And, there has been significant interest, since the outbreak of SARS-CoV-2, in the potential of using Remdesivir in people with the disease caused by the virus, COVID-19.

The current study was conducted at NIAID’s Rocky Mountain Laboratories in Hamilton, Montana. The work involved three groups of animals: those treated with remdesivir 24 hours before infection with MERS-CoV; those treated 12 hours after infection (close to the peak time for MERS-CoV replication in these animals); and untreated control animals.

The scientists observed the animals for six days. All control animals showed signs of respiratory disease. Animals treated before infection fared well: no signs of respiratory disease, significantly lower levels of virus replication in the lungs compared to control animals, and no lung damage. Animals treated after infection fared significantly better than the control animals: disease was less severe than in control animals, their lungs had lower levels of virus than the control animals, and the damage to the lungs was less severe.

The scientists indicate that the promising study results support additional clinical trials of remdesivir for MERS-CoV and COVID-19, the disease that SARS-CoV-2 causes. Several clinical trials of remdesivir for COVID-19 are underway in China, and other patients with COVID-19 have received the drug under a compassionate use protocol.

The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services, also provided support for this study. Gilead Sciences developed remdesivir, also known as GS-5734, and collaborated in the research.

MERS-CoV emerged in Saudi Arabia in 2012. Through December 2019, the World Health Organization had confirmed 2,499 MERS-CoV cases and 861 deaths (or about 1 in 3). Because about one-third of MERS-CoV cases spread from infected people being treated in healthcare settings, the scientists suggest that remdesivir could effectively prevent disease in other patients, contacts of patients, and healthcare workers. They also note the drug might help patients who are diagnosed with MERS or COVID-19 if given soon after symptoms start.

Previous articleTop 10 Life Sciences Jobs Most in Demand over the Next Decade
Next articleAlzheimer’s Disease and Tau Tangle Proteinopathies Linked to Protein that Prevents Tau Clearance